

ASX Announcement



Medibio Limited – 11 November 2022

RESIGNATION OF DIRECTOR AND RESOLUTION WITHDRAWAL

Melbourne, Australia and Minneapolis, MN – 11 November 2022: Medibio Limited (MEB or the Company) (ASX: MEB) (OTCPINK: MDBIF), announces the resignation of Mr Stephen Mitchley as a Director of the Company. Mr Mitchley has elected to resign from the Medibio board as he did not feel he had capacity to fully serve the director role given increases in scope of his role.

Mr Mitchley remains committed to assisting Medibio's growth, in his personal capacity, as he is passionate about the potential that Medibio has to assist in early detection and intervention in mental wellbeing.

Mr David Trimboli, Chair of Medibio Limited said: *"On behalf of the Board I would like to thank Stephen for his contribution to the Company over his tenure and wish him all the best in his future endeavours."*

Therefore, the Company also announces the withdrawal of Resolution 2 from today's Annual General Meeting as set out within the Notice of Meeting announced on the ASX on 10 October 2022. Resolution 2 related to the election of Mr Stephen Mitchley.

The withdrawal of this item of business does not affect the validity of the proxy form attached to the Notice of Annual General Meeting being held on 11 November 2022 or any proxy votes already submitted in respect of the remaining resolutions to be put to shareholders for approval.

ENDS

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The Company was founded in Australia, with offices located in Melbourne (Vic) and Minneapolis (MN). Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Medibio Investor Enquiries:

Medibio Investor Relations
investors@medibio.com.au
+61 3 9692 7222